Argonath delivers heavy-duty containerized BESS – 20ft & 40ft battery storage, liquid cooling, fire suppression, PCS & EMS for utility and C&I projects across Europe.
HOME / Evelo biosciences inc - Argonath Heavy-Duty Containerized BESS Systems
E velo Biosciences, a startup hoping to use the trillions of microbes in and on the human body to fight disease, is shutting down after running low on cash and seeing multiple drug trial...
In an SEC filing, the Massachusetts-based startup, which was founded by Flagship Pioneering in 2015, said that the board has approved the plan of dissolution, deeming it in the best interests of the
(State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Evelo Biosciences, Inc. [ EVLO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic
On December 15, 2022 (the “Closing Date”), Evelo Biosciences, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance
Find the latest Evelo Biosciences, Inc. (EVLO) stock quote, history, news and other vital information to help you with your stock trading and investing.
View Evelo''s SEC filings Direct all inquiries to evelo@vlpc © Evelo Biosciences, Inc.
VC shops including Flagship, GV and Celgene anointed Evelo as
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAXTM medicines as a new modality of orally
CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally
The Investor Relations website contains information about Evelo Biosciences''s business for stockholders, potential investors, and financial analysts.
Evelo Biosciences is shutting down, a move that follows a series of clinical trial setbacks, a corporate downsizing, and the failure to secure additional financing to continue its work...
The Investor Relations website contains information about Evelo Biosciences''s business for stockholders, potential investors, and financial analysts.
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered